Elsevier

Vaccine

Volume 29, Issue 14, 21 March 2011, Pages 2561-2567
Vaccine

The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice

https://doi.org/10.1016/j.vaccine.2011.01.060Get rights and content

Abstract

As an adaptor molecule in the retinoic acid-inducible gene-I (RIG-I) signaling pathway, the virus-induced signaling adaptor (VISA) molecule activates NF-κB and IRF3 and thereby leads to the production of type I interferons (IFNs). To explore the potential of VISA as a genetic adjuvant for DNA vaccines, a eukaryotic expression plasmid, pVISA, was generated by cloning the VISA gene into the pVAX1vector. For comparison, the pTRIF plasmid was similarly constructed, encoding the known genetic adjuvant TRIF (TIR-domain-containing adapter-inducing interferon-β), an adapter in the Toll-like receptor (TLR) signaling pathway. Mice were immunized with the chimeric DNA vaccine pHA/NP147–155, which encodes the HA (hemagglutinin) fused with NP (nucleoprotein) CTL epitope (NP147–155) of H5N1 influenza virus, either alone or in combination with pVISA or pTRIF. Antigen-specific immune responses were examined in immunized mice. Our results demonstrate that co-immunization of the pHA/NP147–155 plasmid with the VISA adjuvant augmented DNA-raised cellular immune responses and provided protection against H5N1 influenza virus challenge in mice. In addition, our data suggest that VISA acts as a stronger adjuvant for DNA immunization than TRIF. We conclude that co-inoculation with a vector expressing the adaptor molecule VISA enhanced the protective immunity against H5N1 infection induced by pHA/NP147–155 and that VISA could be developed as a novel genetic adjuvant for DNA vaccines.

Introduction

The influenza A virus is able to cause severe morbidity and mortality to susceptible humans, making it one of the most deadly infectious pathogens. In 1997, a highly pathogenic avian H5N1 influenza virus was first reported to be transmitted from poultry to humans in Hong Kong, resulting in 18 infected people and six deaths [1]. During the period from 2003 to December 2010, 510 confirmed cases of human infection with H5N1 influenza viruses have been reported around the world, resulting in 303 deaths (http://www.who.int/csr/disease/avian_influenza). Although there have only been a few reports of direct human-to-human H5N1 transmission to date, H5N1 could potentially overcome this obstacle by reassortment with co-circulating human H1N1 or H3N2 influenza viruses [2], which may lead to the emergence of a pandemic influenza virus that could spread rapidly in the human population [3], [4].

Vaccination is currently the most effective method to reduce influenza virus transmission, as well as the associated socio-economic burden [5], [6]. The main forms of licensed human influenza virus vaccines are the traditional trivalent inactivated influenza vaccines, which are comprised of antigens from three circulating virus strains, currently including H1N1, H3N2 and influenza B. However, the difficulties associated with the egg-based production of traditional avian influenza vaccines, including the low yield of candidate vaccine viruses in chicken embryos, the necessity for biosafety level 3 containment facilities, and the poor immunogenicity of H5 hemagglutinin (HA) [7], have encouraged the development of new H5N1 vaccine strategies. As novel vaccine candidates, DNA vaccines have been proven to induce effective antibody response and long-term cell-mediated immunity in animal models [8], [9], [10], [11], [12], [13]. DNA vaccines are also stable, inexpensive and relatively simple to prepare. However, the magnitude of the immune response elicited by DNA vaccines in larger animals, including humans, has been disappointing [14]. Considerable effort has been made to improve the efficacy of DNA vaccines, including optimizing the plasmid delivery system [15], [16], improving antigen uptake and/or presentation [17], [18], combining DNA vaccines with different prime–boost vaccination strategies [19], and co-delivering cytokines to up-regulate the immune responses to the antigens [20], [21], [22], [23], [24], [25].

Viral infection results in induction of type I IFNs, including IFN-β and IFN-α family cytokines [26], [27], [28]. IFN-α/β play a key role in mediating both the induction of the innate immune response and the subsequent development of adaptive immunity to viruses [29], [30], [31]. At least two distinct mechanisms have been proposed for the production of IFN-α/β by virus-associated molecules [29], [30]. One mechanism is mediated by TLRs, such as TLR3, which recognizes viral dsRNA released by infected cells [32]. Viral dsRNA binds to TLR3 and triggers TRIF-mediated signaling pathways, leading to IRF-3 and NF-κB activation [33], [34], [35]. Another mechanism involves retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5), which function as cytoplasmic viral RNA sensors [36], [37]. It has been shown that RIG-I-mediated signaling is independent of TLR3 and TRIF [36]. In the RIG-I pathway, the virus-induced signaling adaptor molecule (VISA, also known as MAVS, IPS-1, or Cardif) plays an essential role in the activation of antiviral signaling [38], [39], [40], [41]. As an adaptor molecule in the RIG-I pathway, VISA is required for the activation of NF-κB and IRF-3 (interferon regulatory factor-3), and its activation therefore leads to the production of type I IFNs. VISA, which localizes to the mitochondria, triggers downstream signaling and is a critical link between mitochondria and innate antiviral immunity [41]. The overexpression of signaling molecules can be used to mimic infection by microbes, thereby eliciting the innate immune responses required for subsequent activation of adaptive immune responses against antigens. It has been found that incorporating the TLR adaptor molecule TRIF into a DNA vaccine triggers TLR signaling and thereby augments DNA-raised adaptive immune responses against the virus [42], [43], [44]. DNA vaccine immunogenicity is also enhanced by co-transfection of IRFs [45]. Adjuvanting a DNA vaccine with a TLR9 ligand together with Flt3 ligand results in enhanced cellular immunity against the corresponding virus [46]. In the present study, we used a mouse model to investigate the potential use of VISA as an adjuvant to augment DNA-raised immune responses against H5N1 and compared this with the TRIF genetic adjuvant.

Section snippets

Mice and viruses

Six-week-old female BALB/c mice were used for immunization and challenge experiments. All mice were maintained with free access to sterile food and water.

The avian H5N1 influenza virus isolate A/chicken/Hubei/489/2004(H5N1) (A/chicken/Hubei/489) and a reassortant influenza virus (A/Viet Nam/1194R) with HA and NA genes of human-isolated influenza virus (A/Viet Nam/1194/2004 (H5N1)) and the internal protein genes of A/Puerto Rico/8/1934 were used in this study. A/Viet Nam/1194R was kindly

VISA activated NF-κB and IFN-β promoters

To investigate whether VISA can be used as a potential genetic adjuvant for DNA vaccines, we tested its ability to activate the NF-κB and IFN-β promoters in Vero cells. The Toll-like receptor adaptor molecule TRIF, a known genetic adjuvant [42], [43] was used for comparison. The pNF-κB-Luc and pIFN-β-Luc reporter constructs were used to measure the activity of the NF-κB and IFN-β promoters, respectively. Our data demonstrate that the overexpression of VISA activated both the NF-κB and IFN-β

Discussion

H5N1 influenza virus continues to pose a public health threat to humans and animals. Consequently, there is an urgent need for effective vaccines against this emerging infectious disease. DNA vaccines hold considerable potential for the prevention and treatment of viral diseases, and studies to assess this strategy for protection against influenza virus have used both envelope and internal viral proteins [8], [12], [18], [48], [51], [57], [58], [59]. However, the early promise of DNA vaccines

Acknowledgments

This work was supported by the National High Technology Research and Development Program (2006AA02Z463) and the National Basic Research Program (2010CB911803) of China.

References (72)

  • D.E. Levy et al.

    The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion

    Cytokine Growth Factor Rev

    (2001)
  • A. Le Bon et al.

    Links between innate and adaptive immunity via type I interferon

    Curr Opin Immunol

    (2002)
  • K.J. Han et al.

    Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways

    J Biol Chem

    (2004)
  • L.G. Xu et al.

    VISA is an adapter protein required for virus-triggered IFN-beta signaling

    Mol Cell

    (2005)
  • R.B. Seth et al.

    Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3

    Cell

    (2005)
  • C. Wan et al.

    The Toll-like receptor adaptor molecule TRIF enhances DNA vaccination against classical swine fever

    Vet Immunol Immunopathol

    (2010)
  • P. Tao et al.

    Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice

    Antiviral Res

    (2009)
  • L.H. Bin et al.

    TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling

    J Biol Chem

    (2003)
  • H.C. Bodmer et al.

    Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein

    Cell

    (1988)
  • R.G. Webster et al.

    Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin

    Vaccine

    (1994)
  • K. Ohba et al.

    Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity

    Vaccine

    (2007)
  • S. Nimal et al.

    Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA

    Vaccine

    (2006)
  • H.A. Yoon et al.

    Cytokine GM-CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses

    Microbiol Immunol

    (2006)
  • S. Nimal et al.

    An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming

    Vaccine

    (2005)
  • T. Kaisho et al.

    Toll-like receptors as adjuvant receptors

    Biochim Biophys Acta

    (2002)
  • C.M. James et al.

    Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein

    Vaccine

    (2007)
  • C.T. Fonseca et al.

    Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone

    Microbes Infect

    (2006)
  • C. Li et al.

    Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence

    Proc Natl Acad Sci USA

    (2010)
  • L. Gillim-Ross et al.

    Emerging respiratory viruses: challenges and vaccine strategies

    Clin Microbiol Rev

    (2006)
  • P. Palese et al.

    Influenza vaccines: present and future

    J Clin Invest

    (2002)
  • T.D. Szucs et al.

    The economic impact of influenza in a university hospital setting

    Infect Control Hosp Epidemiol

    (2001)
  • J.J. Donnelly et al.

    Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus

    Nat Med

    (1995)
  • J.J. Donnelly et al.

    DNA vaccines

    Annu Rev Immunol

    (1997)
  • E. Raz et al.

    Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses

    Proc Natl Acad Sci USA

    (1994)
  • J.J. Donnelly et al.

    DNA vaccines: progress and challenges

    J Immunol

    (2005)
  • A. Luckay et al.

    Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques

    J Virol

    (2007)
  • Cited by (11)

    • Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates

      2020, Vaccine
      Citation Excerpt :

      The five remaining mice were kept under daily observation for 15 days and their survival rate was calculated. Serum antibody titers were determined by enzyme linked immunosorbent assay (ELISA) and the hemagglutination inhibition (HI) assay as described previously [25,27,28]. For the ELISA assay, 96-well microtiter plates were coated with 100 µl/well (5 µg/ml) of inactive H5N1 or NDV.

    • Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection

      2016, Vaccine
      Citation Excerpt :

      In VISA-knockout mice, RSV infection led to increased inflammation and reduced viral clearance [62]. A polypeptide derived from the caspase recruitment domain (CARD) of VISA was found to serve as an adjuvant, inducing an Ag-specific Th1-type immune response [63] and co-inoculation of DNA encoding VISA enhanced antigen-specific cellular immune responses and antiviral effects [64]. Therefore, we explored the potential of VISA as a genetic adjuvant of RSV vaccine.

    • A systematic review of SARS-CoV-2 vaccine candidates

      2020, Signal Transduction and Targeted Therapy
    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    View full text